Breaking Finance News

A statement released earlier today by RBC Capital Markets about Concordia Healthcare Corp (TSE:CXR) bumps the target price to $18.00

Boasting a price of $6.63, Concordia Healthcare Corp (TSE:CXR) traded -5.85% lower on the day. With the last close down -76.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Concordia Healthcare Corp has recorded a 50-day average of $11.78 and a two hundred day average of $27.51. Volume of trade was down over the average, with 350,167 shares of CXR changing hands under the typical 851,752

RBC Capital Markets bumped up the target of Concordia Healthcare Corp (TSE:CXR) to $18.00 stating a potential upside of 1.71%.

On Tuesday September 20, 2016, RBC Capital Markets released a statement on Concordia Healthcare Corp (TSE:CXR) bumped up the target price from $0.00 to $18.00 that suggested an upside of 1.63%.

Performance Chart

Concordia Healthcare Corp (TSE:CXR)

With a total market value of $0, Concordia Healthcare Corp has with a one year low of $5.80 and a one year high of $28.35 .

A total of 10 analysts have released a research note on CXR. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $18.43.

More About Concordia Healthcare Corp (TSE:CXR)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.